DOI:

Effects of preoperative tricuspid regurgitation on mitral regurgitation treatment with the MitraClip device in high-risk patients

Taramasso M., Denti P., Cioni M., Latib A., Buzzatti N., La Canna G., Alfieri O., Colombo A., Maisano F.

Treatment and consequences of regurgitation during transcatheter valve therapies

Effects of preoperative tricuspid regurgitation on mitral regurgitation treatment with the MitraClip device in high-risk patients

Aims: Purpose of the study is to characterise high-risk patients with mitral regurgitation (MR) treated with the MitraClip device (Abbott Vascular, Abbott Park, IL, USA) and to assess the impact of preoperative TR≥3+ on the outcomes at mid-term follow-up after MitraClip treatment.

Methods and results: From November 2008 to March 2012, 106 consecutive patients with degenerative and functional moderate to severe or severe MR underwent MitraClip implantation at our institution. All the patients were assessed by a preoperative standardised protocol, which included TEE, angiography and evaluation of the surgical risk. The functional status was assessed by 6 MWT, while quality of life was evaluated by MLHFQ and SF-36 questionnaires. Short and mid-term outcomes of patients with and without concomitant TR≥3+ (TR group and no-TR group, respectively) were compared. Preoperative TR≥3+ was present in 21/106 patients (19.8%). Patients of the two groups were similar for age, comorbidities and expected surgical risk. Functional aetiology was present in 71.4% of the TR group and in 70.6% of the no-TR group (p=0.9). Preoperative echocardiography showed similar LVEDD (p=0.5) and LVEF (p=0.4). Patients of the TR group had worse quality of life (MLHFQ 44.7 vs. 36.9- p=0.04; SF-36 physical domain 30.4 vs. 36.6 –p=0.004). In-hospital mortality was 0% in TR group and 1.2% in no-TR group (p=0.6). Similar reduction of MR to ≤2+ before discharge was achieved in the two groups (TR group=90.5%, no-TR group=91.6%, p=0.8). At one-year follow-up, actuarial survival was 79.4±10.6% for TR group and 91.1±3.9% for no-TR group (p=0.5) while freedom from MR≥3+ was 67.7±12.1% for TR group and 85.1±5.1% for no-TR group (p=0.04). At last follow-up (mean 9.2 months, range 1-41 months), overall freedom from death, MR≥3+ and rehospitalisation for HF was 47.6% for TR group and 69% for no-TR group (p=0.06). Significant reduction in LV dimensions was observed at follow-up in no-TR group: LVEDD decreased from 66.1±9.4 mm to 62.9±9.1 (p=0.04); LVEDD did not significantly change in TR group (from 66.2±10.6 mm to 69.4±6.5; p=0.3). The presence of preoperative TR≥3+ was identified as predictor of recurrence of MR≥3+ (OR 3.75).

Conclusions: The presence of preoperative TR is associated with more impaired quality of life in MitraClip candidates. Moreover, in patients with significant TR, the recurrence of MR≥3+ and the incidence of composite outcome of death, MR recurrence and rehospitalisation for HF results were higher at mid-term follow-up. Reverse remodelling at follow-up is more likely to occur in patients without preoperative TR.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved